• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转移至胸膜的恶性肿瘤。

Malignancy metastatic to the pleura.

作者信息

Sahn S A

机构信息

Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, USA.

出版信息

Clin Chest Med. 1998 Jun;19(2):351-61. doi: 10.1016/s0272-5231(05)70082-4.

DOI:10.1016/s0272-5231(05)70082-4
PMID:9646986
Abstract

Malignancy is one of the most common causes of exudative effusions and increases in incidence in the elderly. Lung cancer is the most common cause of malignant effusion caused by contiguous spread and its propensity to invade the pulmonary vasculature and embolize to the visceral pleura. Lung, breast, ovary, and gastric cancer and lymphomas account for about 80% of all malignant effusions. Dyspnea and cough are the most common symptoms at presentation. Thirty percent of patients have a low pleural fluid pH (> or = 7.30) and glucose (> 60 mg/dL) at presentation, which predicts a decreased survival, an increase yield on diagnostic studies, and a poor response to chemical pleurodesis. Talc by poudrage or slurry is the most successful pleurodesis agent. Pleural peritoneal shunt is an option for patients with an intractable, symptomatic malignant effusion who cannot undergo or who have failed pleurodesis.

摘要

恶性肿瘤是渗出性胸腔积液最常见的病因之一,且在老年人中的发病率呈上升趋势。肺癌是因连续性扩散导致恶性胸腔积液最常见的病因,其易于侵犯肺血管并栓塞至脏层胸膜。肺癌、乳腺癌、卵巢癌、胃癌及淋巴瘤约占所有恶性胸腔积液的80%。呼吸困难和咳嗽是最常见的临床表现。30%的患者在就诊时胸腔积液pH值较低(≥7.30)且葡萄糖含量较高(>60mg/dL),这预示着生存率降低、诊断性检查阳性率增加以及对化学性胸膜固定术反应不佳。经粉撒法或悬液法使用的滑石粉是最成功的胸膜固定剂。对于有顽固性、有症状的恶性胸腔积液且无法接受或胸膜固定术失败的患者,胸膜腹膜分流术是一种选择。

相似文献

1
Malignancy metastatic to the pleura.转移至胸膜的恶性肿瘤。
Clin Chest Med. 1998 Jun;19(2):351-61. doi: 10.1016/s0272-5231(05)70082-4.
2
[Complications of malignant tumors--malignant pleural effusions].[恶性肿瘤的并发症——恶性胸腔积液]
MMW Fortschr Med. 2004 May 20;146(21):40-2.
3
Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases.转移性胸膜癌的生存情况及滑石粉胸膜固定术:125例报告
Chest. 1993 Nov;104(5):1482-5. doi: 10.1378/chest.104.5.1482.
4
[Thoracocentesis for the assessment of lung cancer with pleural effusion].[胸腔穿刺术用于评估伴有胸腔积液的肺癌]
Arch Bronconeumol. 2002 Oct;38(10):479-84. doi: 10.1016/s0300-2896(02)75269-1.
5
[Talc pleurodesis in malignant pleural effusions].[滑石粉胸膜固定术治疗恶性胸腔积液]
Pneumologie. 2006 Feb;60(2):89-95. doi: 10.1055/s-2005-919139.
6
Management of malignant pleural effusions.恶性胸腔积液的管理
Monaldi Arch Chest Dis. 2001 Oct;56(5):394-9.
7
Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH.胸腔镜滑石粉喷洒治疗恶性胸腔积液:尽管胸腔pH值较低,但胸膜固定术仍有效。
Chest. 1998 Apr;113(4):1007-12. doi: 10.1378/chest.113.4.1007.
8
Thoracoscopic management of malignant pleural effusions.恶性胸腔积液的胸腔镜治疗
Clin Chest Med. 1995 Sep;16(3):505-18.
9
Malignant pleural diseases.恶性胸膜疾病
Monaldi Arch Chest Dis. 2000 Feb;55(1):17-9.
10
Lung cancer and ipsilateral pleural effusion.肺癌和同侧胸腔积液。
Ann Oncol. 1995;6 Suppl 3:S25-7. doi: 10.1093/annonc/6.suppl_3.s25.

引用本文的文献

1
Clinical overview of the physiology and pathophysiology of pleural fluid movement: a narrative review.胸腔积液流动的生理学与病理生理学临床概述:一篇叙述性综述
ERJ Open Res. 2024 Sep 30;10(5). doi: 10.1183/23120541.00050-2024. eCollection 2024 Sep.
2
Estimation of disability free life expectancy in non small cell lung cancer based on real world data.基于真实世界数据的非小细胞肺癌无残疾预期寿命估计。
Sci Rep. 2023 Aug 16;13(1):13318. doi: 10.1038/s41598-023-40117-5.
3
Tension hydrothorax in a patient with a history of pulmonary tuberculosis.
一名有肺结核病史患者的张力性胸腔积液。
Respir Med Case Rep. 2023 May 22;44:101868. doi: 10.1016/j.rmcr.2023.101868. eCollection 2023.
4
Imaging Features of Various Benign and Malignant Tumors and Tumorlike Conditions of the Pleura: A Pictorial Review.胸膜各种良性和恶性肿瘤及肿瘤样病变的影像学特征:图谱综述
Taehan Yongsang Uihakhoe Chi. 2020 Sep;81(5):1109-1120. doi: 10.3348/jksr.2019.0165. Epub 2020 Aug 13.
5
A 58-Year-Old Man with a Painful Gluteal Mass as the First Presentation of Metastatic Adenocarcinoma of the Lung.一名58岁男性,以臀部长有疼痛性肿块为首发表现的肺转移性腺癌
Am J Case Rep. 2021 Mar 5;22:e928122. doi: 10.12659/AJCR.928122.
6
Management of Malignant Pleural Effusions and Malignancy-Related Ascites.恶性胸腔积液和恶性肿瘤相关性腹水的管理
Semin Intervent Radiol. 2020 Oct;37(4):434-440. doi: 10.1055/s-0040-1715885. Epub 2020 Oct 1.
7
Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the Tumor.通过胸腔积液诊断出具有小细胞癌成分的肺癌以及通过肿瘤诊断出具有鳞状细胞癌成分的肺癌。
Intern Med. 2018 Dec 1;57(23):3419-3422. doi: 10.2169/internalmedicine.1200-18. Epub 2018 Jul 6.
8
Management of malignant pleural effusion: challenges and solutions.恶性胸腔积液的管理:挑战与解决方案
Cancer Manag Res. 2017 Jun 23;9:229-241. doi: 10.2147/CMAR.S95663. eCollection 2017.
9
Transudative pleural effusion of malignant etiology: Rare but real.恶性病因的漏出性胸腔积液:罕见但确实存在。
Respir Med Case Rep. 2017 Feb 28;20:188-191. doi: 10.1016/j.rmcr.2017.02.015. eCollection 2017.
10
Predictive models of malignant transudative pleural effusions.恶性漏出性胸腔积液的预测模型。
J Thorac Dis. 2017 Jan;9(1):106-116. doi: 10.21037/jtd.2017.01.12.